Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Fredun Pharmaceuticals Limited (NSE: FREDUN), ISIN INE194R01017 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
FREDUN last traded at ₹1512.25 (+2.69%), with a 52-week range of ₹1195.20 to ₹1665.00 (as of 6 Nov 2026).
Shareholding as of Sep 2026: promoters 43.62%, FIIs 0.69%, DIIs 3.43%, mutual funds 0.00%.
EquiSense Score (ECS): 80/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.